Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00283439
Status:
COMPLETED
Last Update Posted:
2011-06-20
First Post:
2006-01-26
Brief Title:
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia CIT in Adults With Lymphoma
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open Label Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi-Cycle Chemotherapy in Adult Subjects With Lymphoma
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to identify a well-tolerated effective dose and schedule of AMG 531 for the treatment of Chemotherapy Induced Thrombocytopenia CIT in subjects with lymphoma receiving multi-cycle chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None